Should Investors Be Worried About Dividend King AbbVie?
28/4 10:42
Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq. AbbVie beat Wall Street's top- and bottom-line estimates...